Navigation Links
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Date:12/10/2012

zartinib and may benefit from its future use. Quizartinib is well tolerated, with gastrointestinal toxicities being the most common as well as reversible QT prolongation which was infrequently grade 3 (with no cases of grade 4 in this patient cohort) at the doses used in this trial. These data suggest that quizartinib may be an attractive option in this heavily pretreated patient population with limited therapeutic options.  The benefit of bridge to HSCT had a clear impact in improving overall survival for these patients.

The Quizartinib Clinical Program
As of Dec. 1, 2012, approximately 450 patients have been enrolled into clinical trials evaluating quizartinib in AML, and in addition to the Phase 2 study presented this week, other ongoing trials with quizartinib include: 

  • "An Open Label Study to Evaluate the Safety and Efficacy of Two Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01565668)"  The purpose of this Phase 2b study is to assess the safety and efficacy of additional dose strengths of quizartinib monotherapy in relapsed or refractory AML patients.  In addition to evaluating clinical response and survival, assessment of PD biomarkers and pharmacokinetics (PK) will be performed.  Patient enrollment started in May 2012, and the study is currently ongoing.
  • "A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT01390337)"  The purpose of this Phase 1 study is to define the maximum tolerated dose of quizartinib when combined with induction and consolidation therapy, and as a maintenance therapy following induction and consolidation.  Patient enrollment is ongoing.
  • "A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) (NCT01468467)"  The purpose of this Phase 1 stud
    '/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
8. Xstelos Holdings Announces Dividend
9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... for quarter ending March 31, 2015 after market ... host a conference call that day at 5:00 ...
(Date:5/4/2015)... , May 4, 2015 Eli ... two new reports that provide a comprehensive overview ... highlight how Lilly is evolving its approach to ... capabilities in partnership with others to have greater, ... Corporate Responsibility Update offers a thorough look ...
(Date:5/4/2015)...  NeuroSigma ® , Inc. (NeuroSigma), a California ... animal study of its Thin Film Nitinol (TFN) flow diverter ... researchers at the 53 rd Annual Meeting of the ... . A copy of the study abstract can be accessed ... at Mayo Clinic was primarily funded through a Small Business ...
Breaking Medicine Technology:Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 2NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 3NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 4
... BIOD ) announced today the retirement of Dr. ... is a co-founder of Biodel and will remain a member ... chairman, president and chief executive officer from its founding in ... was named the company,s president and chief executive officer and ...
... 2010 Reportlinker.com announces that a new ... catalogue: Asia-Pacific Markets for ... 2011 http://www.reportlinker.com/p0339835/Asia-Pacific-Markets-for-Cardiac-Rhythm-Management-Electrophysiology--Ablation-Devices-2011.html ... Pacific markets for cardiac rhythm management (CRM), ...
Cached Medicine Technology:Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 2Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 3Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 4Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21
(Date:5/4/2015)... 2015 TROY Healthcare Solutions is proud ... Regional User Group (RUG) Conference in Baltimore, MD from ... Regional User Group provides an opportunity for clients to ... exhibitor gallery. , In addition to sponsoring the event, ... North Atlantic RUG Conference. Attendees can stop by the ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The American ... critical state policy reports which identify gaps in coverage ... “After ATA issued the State Telemedicine Gaps Reports last ... how their laws and regulations impact healthcare delivery in ... a result of state actions across the nation, ATA ...
(Date:5/4/2015)... Baptist Medical Center Jacksonville has received ... The Guidelines®-Stroke Gold Plus Quality Achievement Award along ... recognizes the hospital’s commitment and success in ensuring ... according to nationally recognized, research-based guidelines based on ... Gold Plus Quality Achievement Award, hospitals must achieve ...
(Date:5/4/2015)... METTLER TOLEDO has announced an ... Integrity in a GXP Regulated Laboratory ", featuring ... webinar will be presented on May 27, 2015 ... is a critical component of pharmaceutical product quality ... in recent years an increasing number of inspections ...
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
Breaking Medicine News(10 mins):Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3
... Platform, Michigan Orthopedic ServicesDETROIT, Feb. 2 Huron Capital ... Services ("MOS") has acquired O&P Professional Care as part ... MI. The business will be managed under the ... disclosed. MOS operates a network of 11 patient ...
... a large, ongoing study to improve detection and prevention ... a specific heart rhythm abnormality idiopathic QT interval ... artery disease. , "More than 80 percent of ... who have significant coronary artery disease, but we currently ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... with simultaneous webcast on Tuesday, February 3, 2009 at ... Rigel,s senior management team will provide an update on ... Webcast Information To access the live call, please dial ...
... 2 In celebration of American Heart Month, ... Forum showcasing a live- telecast of the ... disease on Tuesday, February 10, 2009. During ... Medical Director of Arizona Heart Institute and Arizona ...
... current rate of production for new mammography professionals, there will ... woman age 40 years and older over the next 15-20 ... Health and Workforce Studies at the Albany School of Public ... the year 2010 there will be approximately 20.6 radiologists per ...
... SANTA MONICA, Calif., Feb. 2 A national consumer ... lobbying positions on the electronic medical record provisions of ... an independent journalist that Google,s presence on the bill ... public policy team for an immediate answer. The letter ...
Cached Medicine News:Health News:Huron Capital Continues Acquisition Activity 2Health News:Rhythm abnormality of unknown origin strongly predicts sudden death risk in heart disease patients 2Health News:Rigel to Host Conference Call on February 3, 2009 2Health News:Arizona Heart Institute Announces FREE Public Forum Featuring Live Viewing of Surgical Procedures Via High-Definition (HD) Satellite 2Health News:Workforce shortages in mammography could threaten early detection rates for breast cancer 2Health News:Consumer Watchdog to Google: Publicly Disclose Your Lobbying Positions on Electronic Medical Record Provisions in Stimulus Bill 2
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Ammonia in plasma...
For the quantitative in vitro determination of Sodium in serum and plasma....
Enzymatic assay for the quantitative in vitro determination of glycated protein (fructosamine) in human serum or plasma....
Medicine Products: